Data, data, data

That's the buzzword: big data. You'll find it in the top articles of 2014 in Health Affairs or in the Forbes Health Care Summit. This summit is where to go if you want to know what's going on in health care in the US, otherwise you cuold have a look at the video. Wether this is really going to create more value widely still remains to be seen.

The politics of calories

Why Calories Count

Marion Nestle says in her book:

In some ways, the calorie environment could not have been more brilliantly constructed to overcome physiological controls of overeating.

The new labeling initiatives have been really minor up to now. Wether they will have beneficial effects in the long run is still unknown. Calorie labeling should be extended when eating outside home and to alcohol.
The government has not paid enough attention to food regulation and specially to information about calories. In the book there is a guide for improvement. This is the previous step in any nudging effort. To be clear, information disclosure is the very beginning of any consumer protection and health promotion policy in this field.

The pivotal role of MSF in global health

Life in Crisis: The Ethical Journey of Doctors Without Borders
MSF: how a humanitarian charity found itself leading the world’s response to Ebola

I've just finished reading a book on MSF, a compelling story of more than 4 decades of support in health and humanitarian crisis.

Life in Crisis tells the story of Doctors Without Borders/Médecins Sans Frontières (MSF) and its effort to save lives on a global scale. Begun in 1971 as a French alternative to the Red Cross, MSF has grown into an international institution with a reputation for outspoken protest as well as technical efficiency. It has also expanded beyond emergency response, providing for a wider range of endeavors, including AIDS care. Yet its seemingly simple ethical goal proves deeply complex in practice. MSF continually faces the problem of defining its own limits. Its minimalist form of care recalls the promise of state welfare, but without political resolution or a sense of well-being beyond health and survival. Lacking utopian certainty, the group struggles when the moral clarity of crisis fades. Nevertheless, it continues to take action and innovate. Its organizational history illustrates both the logic and the tensions of casting humanitarian medicine into a leading role in international affairs.

Their achievements are really impressive and nobody can imagine what could have happened this year with the Ebola outbreak without them. To understand their contribution I would like to recommend the article in BMJ:

 The charity had a team in Guinea when the outbreak began in March and has followed the virus as it has spread—building treatment centres in locations as disparate as the jungle and capital cities, deploying mobile units, providing technical support to governments, and training staff. Today MSF has more than 3400 staff on the ground (with one international staff member for every 10 local staff members) and says that it has cared for almost 4000 patients confirmed to have Ebola and many more suspected cases.

 We all have to appreciate their enormous work in such a difficult conditions and their example offers a good guide to understand that beyond governments, well organised nonprofit institutions play a critical role in supporting public health.

PS. I am quite concerned about the nurse's behaviour in the spanish ebola case. Yesterday she admitted that she hadn't told the physician about her exposure to an ebola case. This situation has strong ethical implications, does anybody care about it?

The growing evidence on compression of morbidity

Health, functioning, and disability in older adults—present status and future implications

There is currently a wide debate about chronic care and multimorbidity. Some messages appear that this is strictly connected with ageing, and forget the details. Though disease process have to be tackled, we have to ask ourselves about wellbeing in later life. A key issue is to understand its impact on functioning and disability. This is precisely what a recent article in The Lancet offers. The research question:

Will the years gained be productive and healthy, or will elderly people live longer lives in conditions of ill health? Three main hypotheses have been proposed to address this question.² The compression of morbidity hypothesis posits a situation for which the age of onset of morbidity is delayed to a greater extent than life expectancy rises, thereby compressing morbidity into a short period at a late age.³ The expansion of morbidity hypothesis maintains the opposite, that increases in life expectancy are matched or exceeded by added periods of morbidity.⁴ Both compression and expansion of morbidity could happen in absolute or relative terms—ie, changes in the absolute number of years lived with disability—or in terms of healthy life expectancy as a proportion of total life expectancy.

And a conclusion:

 Our systematic examination of the scientific literature shows that support for morbidity pattern hypotheses varies mainly according to the type of health indicator. Disability-related or impairment-related measures of morbidity tend to support the theory of compression of morbidity, whereas chronic disease morbidity tends to support the expansion of morbidity hypothesis.

This is an article to read and file for the future. The basic approach is defined, the difficulty is about the data. My impression is that we need to use morbidity adjusted life expectancy measures, as those I presented in this blog some months ago. The advantages are clear compared to healthy life expectancy that needs a lot of hypothesis and are based on surveys and self perceptions. Morbidity adjusted measures use  disease codes directly. Why not apply them widely?

PS. The whole series on ageing in The Lancet.

Fasten seat belts (3)

My former posts (1) and (2) alerted about the end of drug pricing as we have known and the begining of an opaque world where nobody knows how much money is involved in getting the value of a specific drug, except the manufacturer. The rationale for that are the confidential agreements between governments and drug firms. Up to now have been seven risk-sharing agreements, and beyond these, central government has set up additional five agreements. This latter agreements are really open-ended budgetary ceelings because it is difficult to estimate when the maximum amount is reached. This is precisely what it is explained by the official in charge of this issue in the journal.
Therefore we have changed the pricing system for an opaque open-ended budgetary ceeling system. It sounds incredible, but that's how it is. I can't believe that nobody worries about it.

PS. Genes and behaviour, on TE. I posted the initial research three years ago in this blog.

Health care under civil conflict

Current situation in Syria deserves a better understanding and international support. Beyond the refugee crisis there is a huge health tragedy:

More than 12 million people are impacted by the violence, with 7.6 million people displaced inside the country and more than 3 million displaced in neighboring nations. Some refugees live in formal camps, but the majority are living in Jordan, Lebanon and Turkey. Refugees have also fled to Egypt and Iraq, and many remain inside Syria but have had to leave their homes. Many have also been affected by the terrorist Islamic State group.

A difficult moment, and things may get worse. I would like to suggest a look at this documentary from PBS Frontline:  The Rise of ISIS in english and in catalan here until Jan 18th.

Involved in our own health

People in control of their own health and care

 From King's Fund report:

Different perspectives (p.11)

• A consumerist approach: health and health care is seen as a marketplace in which patients (consumers) are involved by making choices about services, and the health care market responds to their preferences. Patient involvement is then a means to improve quality.
• A democratic approach: people have political, social and economic rights as citizens, and those who use or are affected by a public service should be involved in how it is run, and have certain rights regarding what they receive from that service.
• An ethical and outcomes-based approach: involvement is seen as the ethical thing to do, and the best approach to improve outcomes. This means recognising that good care comprises the application to individual circumstances of evidence-based medicine along with knowledge and experience. Patient involvement is essential to the judgement of relative risk and benefit associated with decision-making.
• A value-based approach: to achieve truly the best value for money from our health and care system, we must know and respond to what people need and want. In this way, we can deliver care that meets their preferences and patients receive ‘the care they need (and no less), and the care they want (and no more)’ (Mulley et al 2012).
• An approach based on sustainability: it is increasingly difficult for health systems to provide the best possible care to everyone as the prevalence of long-term conditions increases and the population ages. By involving people in managing their own health and care, and keeping well and independent, we can minimise our use of services.
• A person-centred care approach: our health and care system should be  focused on its users, promoting independence and co-ordinated around people’s full needs rather than being fragmented and siloed. Patient involvement is an essential component of delivering a more person-centred service that is tailored and responsive to individual needs and values.

The forgotten perspective in the list, though quoted in the text (p.16):  A behavioural economics approach: we try to do our best for our health but the autopilot decides without our full control. Some help (nudging) is needed.

The message:  "Embarking on an honest conversation about rights and responsibilities requires consideration of people’s motivation and the capability to engage."

PS. Nudging and the European Union, by Alberto Alemano.

PS. BIT Publication: EAST.Four simple ways to apply behavioural insights

PS. Regarding Hepatitis C treatment costs, It is good to remember this post by U. Reinhardt:

With this offer curve, a health system confronts the rest of the nation with two morally challenging questions:

1. Is there a maximum price above which society no longer wishes to purchase added QALYs from its health system, even with the most cost-effective treatments (e.g., Point C)?

2. Should that maximum price be the same for everyone, or could there be differentials – for example, a lower maximum price for patients covered by taxpayer-financed health programs (e.g., Medicaid, Tricare, the Veterans Administration health system and perhaps Medicare), a wide range of higher prices for premium-financed commercial insurance, depending on the generosity of the benefit package that the premium covers, and yet higher prices for wealthy people able to pay out of their own resources very high prices to purchases added QALYs for the family?